DSpace DSpace UPC
 Català   Castellano   English  

E-prints UPC >
Altres >
Enviament des de DRAC >

Empreu aquest identificador per citar o enllaçar aquest ítem: http://hdl.handle.net/2117/6524

Ítem no disponible en accés obert

Arxiu Descripció MidaFormat
Diez J - Expert Rev Cardiov Ther 2009.pdfArtículo principal244,56 kBAdobe PDFThumbnail
Veure/Obrir

Citació: Díez, J. [et al.]. Torafic study protocol: torasemide prolonged release versus furosemide heart failure. "Expert review of cardiovascular therapy", 2009, vol. 2009, p. 897-904.
Títol: Torafic study protocol: torasemide prolonged release versus furosemide heart failure
Autor: Díez, Javier; Coca, Antonio; Teresa, Eduardo de; Anguita, Manuel; Castro-Beiras, Alfonso; Conthe, Pedro; Cobo Valeri, Erik Veure Producció científica UPC; Fernández, Ester
Data: 2009
Tipus de document: Article
Resum: Loop diuretics, such as torasemide and furosemide, are important agents in the treatment of chronic heart failure. Beneficial effects of torasemide immediate-release formulation beyond diuresis have been documented as the ability of this compound to inhibit myocardial synthesis and deposition of collagen type I in patients with chronic heart failure. In addition, torasemide-treated patients, but not furosemide-treated patients, showed decreased serum concentrations of the C-terminal propeptide of procollagen type I, a biochemical marker of myocardial fibrosis. The aim of the TORAFIC study is to test the efficacy of torasemide prolonged-release formulation (PR) in reducing myocardial fibrosis in chronic heart failure in a large, randomized clinical trial. METHODS: This prospective, Phase IV, randomized, blinded end point, active-controlled clinical trial will randomize 142 patients with chronic heart failure in New York Heart Association functional class II-IV to 8 months treatment with either torasemide-PR (10-40 mg daily) or furosemide (40-160 mg daily). The primary objective is to test the hypothesis that torasemide-PR is superior to furosemide in reducing myocardial fibrosis. The primary outcome measure is the difference in the change of serum propeptide of procollagen type I concentration from the initial to the final visit between both study groups. Secondary outcome measures include all efficacy variables related to heart failure (signs and symptoms, ECG, echocardiogram and serum levels of N-terminal brain natriuretic propeptide). Secondary safety variables are heart rate, blood pressure, laboratory data, adverse events, cardiovascular events (hospital admission, emergency department visits) and quality of life (Minnesota questionnaire). DISCUSSION: This trial will test whether torasemide-PR possesses antifibrotic properties, which may provide an additional benefit beyond diuresis in patients with chronic heart failure.
ISSN: 1477-9072
URI: http://hdl.handle.net/2117/6524
DOI: 10.1586/ERC.09.74
Versió de l'editor: www.expert-reviews.com
Apareix a les col·leccions:GREMA - Grup de Recerca en Estadística Matemàtica i les seves Aplicacions. Articles de revista
Departament d'Estadística i Investigació Operativa. Articles de revista
Altres. Enviament des de DRAC
Comparteix:


Stats Mostra les estadístiques d'aquest ítem

SFX Query

Aquest ítem (excepte textos i imatges no creats per l'autor) està subjecte a una llicència de Creative Commons Llicència Creative Commons
Creative Commons

 

Valid XHTML 1.0! Programari DSpace Copyright © 2002-2004 MIT and Hewlett-Packard Comentaris
Universitat Politècnica de Catalunya. Servei de Biblioteques, Publicacions i Arxius